Remove Molecular Biology Remove Pharmaceutical Companies Remove Small Molecule
article thumbnail

Sosei Heptares’ COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development

The Pharma Data

To date, the Company has applied its world-leading structure-based drug design (SBDD) capabilities and cutting-edge technologies to precision-design new inhibitors of the SARS-CoV-2 M pro protease, which plays a crucial role in viral replication 1-4.

article thumbnail

The evolution of cell therapy to address unmet medical needs

Drug Target Review

Also, many companies never reached the point where they received validation from big pharmaceutical companies. Transplanting cells could prove to be more beneficial than treating a particular condition with a small molecule or an antibody, and that really speaks to the power of cell therapy.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Women in Stem with Lidia Pieri

Drug Target Review

Sibylla’s scientific founders come from very different scientific fields that do not usually speak to each other, such as theoretical physics, molecular biology and pharmaceutical chemistry. And so, I have been the managerial co-founder and CEO of Sibylla since 2017. Identifying new drugs is an extremely complex project.

article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

Harini Srinivasan is a Principal Scientific Associate at Serna Bio with over 10 years of research experience in academic institutions, health care organizations and pharmaceutical companies. Fascinated by the potential of AI in medical research, I transitioned to BenevolentAI in early 2023 as a Biology Project Leader.